FDA approves bremelanotide (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as treatment for HSDD.
Bremelanotide is self-administered with a disposable autoinjector that activates melanocortin receptors. Patients inject Vyleesi (bremelanotide) under the skin of the abdomen or thigh a minimum of 45 minutes before sexual activity.
Common side effects are nausea, headaches and flushing.
Read the Full FDA Press Release here.